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Abstract
The role of milk and milk proteins in relation to human health remains controversial.
However, there is a large body of evidence, reviewed in this paper, specifically linking
A1 beta-casein to a range of illnesses.
A1 beta–casein is produced only by cattle of European origin.  The proportion of
European cattle producing A1 beta-casein varies by breed and country.  High levels are
found in many parts of northern Europe and also other parts of the world where particular
breeds of European origin predominate. Cattle that produce A2 and not A1 beta-casein
are known as A2 cattle.  A2 beta-casein was the original variant.
A1 beta-casein releases bovine beta-casomorphin7 (BCM7) on digestion.  The amount
and stability of BCM7 that is cleaved from A1 beta-casein is linked to the presence and
levels of various enzymes, in particular dipeptidyl peptidase 4.  BCM7 is a strong opioid.
There are seven strands to the evidence linking A1 beta-casein and BCM7 to Type 1
diabetes.  These include particularly strong correlations amongst developed countries
between A1 beta-casein intake and Type 1 diabetes incidence (r2 =0.84, p<0.00001).
Supporting evidence comes from biochemistry (structure of A1 beta-casein and cleavage
of BCM7), pharmacology (opioid characteristics and binding affinities of BCM7), animal
trials (NOD mice and BB rats), immunology (people with Type 1 diabetes have enhanced
levels of antibodies to beta-casein and in particular A1 beta-casein), and human studies
(high milk intake in children linked to high incidence of diabetes).  A plausible auto
immune mechanism relates to the homology between an amino acid sequence in both
BCM7 and the GLUT2 glucose transporting molecule produced within the pancreas.
Countries with high levels of Type 1 diabetes are the same countries that have high levels
of heart disease (r2=.74, p<0.001).  This strongly suggests linked factors of causation.  A1
beta casein intake also correlates strongly with heart disease (r2 up to 0.86, p<0.001).
Supporting evidence includes an animal trial with rabbits, and LDL oxidation by BCM7.
BCM7 has also been linked to symptoms of autism and schizophrenia (animal and human
trials) and BCM7 has been widely reported in urine of autistic people.
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Intestinal and stomach permeability appears to be a common feature of all conditions
where A1 beta-casein has been implicated.  This permeability occurs in all babies and can
occur for a range of health reasons in children and adults.
The debate about A1 and A2 beta-casein has largely been occurring in NZ and Australia.
NZ has been typing all breeding bulls for A1/A2 status for approximately 10 years, and
the national herd is drifting towards A2.  However this is mainly because of a
serendipitous association between A2 cattle and particular characteristics that are sought
within the NZ breeding system (high protein production efficiency rather than milk
production per cow).  The national herd could convert to A2 over about a 10 year period.
No other countries are routinely typing their bulls for A1/A2 status.
Although the scientific and medical evidence is published in peer reviewed journals it has
not been widely reviewed as an integrated body of evidence.  This paucity is linked to the
breadth of encompassed disciplines.  Further, much of the early research was undertaken
from within the mainstream dairy industry, particularly in NZ.  This industry has
subsequently chosen to regard the A1 versus A2 issue as a threat rather than an
opportunity, and has mounted a sophisticated public relations and political campaign that
A1 versus A2 is a non issue.
***
Introduction
Mainstream medical opinion holds that milk is a nutritious food of benefit to most people.
However, an extensive body of evidence now exists that one particular protein, called A1
beta-casein, which is present in the milk of some but not all cows, is linked to Type 1
diabetes, heart disease and symptoms of autism and schizophrenia.  It may also be
implicated in an additional range of auto-immune conditions.  This protein is also linked
to milk intolerance in some people.
Milk that does not contain A1 beta-casein, but contains the alternate A2 beta casein, is
known as A2 milk.  Cows that produce beta-casein that is solely of the A2 type are
known as A2 cows.
If A1 beta-casein is indeed causally related to some or all of these conditions, then it does
not mean that at-risk individuals need to avoid milk and milk products.  But it does mean
that the milk products should come from A2 cows.
The distinguishing amino-acid sequence that characterises A1 beta–casein is essentially
unique to some European cattle.1  African and Asian cattle, unless carrying some
European genes, are A2.  Goats, sheep, yaks and camels all produce milk that is of the A2
type.  Human beta-casein is also of the A2 type as defined by the relevant amino-acid
sequence.2
It is apparent that the A1 mutation in European cattle first appeared some thousands of
years ago.3  The proportion of modern European cattle producing A1 beta-casein varies
by breed and country.  Currently, high levels are found in many parts of northern Europe,
and also wherever particular northern European cattle breeds predominate.  It is probable
but not proven that the level of A1 beta-casein in milk has increased over the last century
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as the Friesian/Holstein (black and white) breeds have become predominant in many
countries.  It is also relevant that milk itself has become a much more important part of
human diets within the last 100 years
There are multiple strands to the evidence linking A1 beta-casein and BCM7 to Type 1
diabetes.  These include epidemiology, biochemistry, pharmacology, immunology,
animal trials, and human studies.  This evidence will be reviewed within this paper.
The major focus within this paper will be on Type 1 diabetes.  However, it is important
that, both as contextual background and also in understanding the overall situation, there
is recognition that A1 beta-casein is also implicated in other disease conditions.  Also
relevant is that intestinal and stomach permeability may be a common feature of all
conditions where A1 beta-casein has been implicated.  This permeability occurs in all
newborn babies and can occur for a range of health reasons in children and adults.
To date, the debate about A1 and A2 beta-casein has largely been occurring in NZ and
Australia.  NZ has been typing all breeding bulls for A1/A2 status for approximately 10
years, and the national herd is now slowly drifting towards A2.  However much of this
drift is because of a serendipitous association between A2 cattle and particular
characteristics that are sought within the NZ breeding system (high protein production
efficiency rather than milk production per cow).  There is no evidence that such a drift to
A2 is occurring elsewhere in the world.  In most countries the national herds could
convert to A2 over about a 10 year period, or more rapidly using new technologies of
sex-selected semen.  However, no other countries apart from New Zealand are routinely
typing their bulls for A1/A2 status.
Although the relevant scientific and medical evidence (more than 100 relevant papers) is
published in peer reviewed journals, it has not been widely reviewed as an integrated
body of evidence.4  This paucity is linked to the breadth of encompassed disciplines.
Most scientists do not read across all of these disciplines and hence the richness of the
overall evidence has been missed.  Further, much of the early research was undertaken
from within the mainstream dairy industry, particularly in NZ.  This industry has
subsequently chosen to regard the A1 versus A2 issue as a threat rather than an
opportunity, and has mounted a sophisticated public relations and political campaign that
A1 versus A2 is a non issue.  This campaign has included non disclosure, misinformation,
and obfuscation.
The issue of A1 beta-casein is therefore not only a story about the medical evidence.  It is
also very much a story about how that evidence has been and is being manipulated.
Where it all started
The scientist who deserves great credit for the initial work and key insights relating to A1
beta-casein and Type 1 diabetes is clearly Professor Bob Elliott, who is with us today as a
commentator on this paper.  Bob Elliott knew from his work in Samoa that there was a
more than 10 fold difference in the incidence of Type 1 diabetes in Samoan children
living in New Zealand compared to Samoan children living in Samoa.  It was obvious
that the factor had to be environmental.  Bob Elliott also knew that Samoan children in
Samoa drank very much less milk than Samoan children in New Zealand, and milk
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therefore stood out as an obvious candidate.  In addition, Bob Elliott also knew from his
own previously published work that casein, or an unidentified component thereof, was
diabetogenic in rodents.5  However, he also knew that the Masai people in Kenya drink
large amounts of milk but that childhood diabetes is extremely rare amongst those who
still live this traditional lifestyle.  In 1993 he therefore approached the NZ Dairy Research
Institute, asked to speak to a milk biochemist, and asked the key insightful question: Are
there any protein differences in the milk that the Masai people drink compared to the milk
that is drunk in New Zealand?  The answer, from NZDRI scientist Dr Jeremy Hill, was
that there is indeed a difference in the beta casein protein.  The milk the Masai people
were drinking contained beta casein that was totally A2 whereas that drunk in NZ
contained major amounts of the A1 beta casein.  It was that question and response that
first led to the hypothesis that A1 beta-casein might be implicated in Type 1 diabetes,
although at that stage the mechanisms by which it might be occurring were totally
unclear.  Indeed Jeremy Hill has subsequently said that he always saw it as a ‘long shot’.6
One of the first steps in testing the hypothesis was to undertake trials with rodents (this
time NOD mice).  The trials were funded by the New Zealand Dairy Board and the
National Children’s Health Research Foundation (a Rotary Charity). The mice were fed a
range of diets, including A1 beta-casein, A2 beta casein, or a combination of the two.
The results showed that 47% of those fed A1 beta-casein developed Type 1 diabetes
whereas none of those fed A2 beta-casein developed diabetes.  In another group fed a
milk formula containing both A1 and A2 casein there was an intermediate 19% level of
diabetes. The differences between the A1 and A2 diets were very highly significant
(p<0.001).  This indicates that the chance of falsely getting a result like this when there is
no underlying cause is less than 1 in 1000.  Supplying naloxone (an opioid antagonist) in
the drinking water of another group of animals fed A1 beta-casein prevented
development of diabetes.
These results were first reported in a patent specification (International Number
PCT/NZ95/0014) by the two sponsoring organisations.  They were also published in a
special publication of the International Dairy Federation.7
There are two potential criticisms of these trials.  The first is that the investigators were
not ‘blinded’ as to which mice were receiving which treatment.  Blinding is a means of
protecting against either fraud or accidental bias, although the measures used to
determine Type 1 diabetes leave minimal scope for subjective bias.  The second criticism
is that the results were not published in an international journal with wide readership.
These initial results have on occasions been described as ‘preliminary’ and they led to a
much larger trial subsequently being set up.  I will return to this subsequent trial later in
this paper, but first I want to address some of the epidemiology and biochemistry of A1
beta-casein.
Epidemiology
One of the startling characteristics of Type 1 diabetes is the huge difference in incidence
between different countries.8  Worldwide, the incidence varies by a factor of at least 300,
with high levels being found in developed countries with western lifestyles and diets.  But
even between highly developed Western-type countries the incidence varies more than
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tenfold.9 More than 65,000 new cases are recorded each year in children under the age of
14.
Analysing the relationship between diabetes incidence at the country level and intake of
A1 beta-casein depends on both accurate ascertainment of diabetes incidence levels, and
accurate knowledge not only of milk intake but of the A1 beta-casein level within that
milk.  Initially there were difficulties getting reliable data both on incidence level and
intake of A1 beta-casein.  But by 1999 Bob Elliott and colleagues had a paper published
in the international journal Diabetologia showing remarkable correlation between Type 1
diabetes incidence and A1 beta-casein incidence for 10 developed countries.10  However,
the most comprehensive paper came somewhat later when more information was
available.  Authored by Dr Murray Laugesen and Bob Elliott, it was published in the NZ
Medical Journal in 2003.11
Laugesen and Elliott found extremely strong relationships at the country level for 19
developed countries between A1 beta-casein and Type 1 diabetes incidence during the
period 1990-1994 (r=0.92, p<0.00001) (Figure 1).  They also compared Type 1 diabetes
incidence with more than 100 other dietary and lifestyle factors but could find nothing
that gave comparable correlations.  By squaring the correlation coefficient (0.922) we can
observe that A1 beta-casein can ‘explain’ some 84% of the variation between countries.
This is a remarkably high figure.
Given that the intake of A1 beta casein is linked both to the intake of milk and the ratio of
A1;A2 beta-casein, it is logical to expect that if the A1 beta-casein relationship is causal
then there will also be a correlation between milk protein intake and Type 1 diabetes.
This is indeed the case (Figure2) but the much lower r2 value of 0.47 indicates that it is
A1 beta –casein that is the important relationship, and that total protein is being dragged
along by the cross correlation..  Similarly, given that A2 beta-casein intake is in part
determined by total milk intake, and hence likely to be cross correlated to A1 beta-casein
intake, one would expect to see a relationship between diabetes incidence and A2 beta-
casein.  This is indeed the case but with an r2 of only 0.22.
Within epidemiology there is ongoing debate as to the weight which should be placed on
between-country analyses, which are sometimes called ecological studies.  However, it is
notable that many major health discoveries have their origins in ecological studies.12  The
potential problem is that it is possible for spurious correlations to occur.  It could be that
A1 beta-casein intake is strongly correlated to some other factor that is the causal factor.
So a high correlation coefficient, even if statistically significant, is not usually regarded
as ‘proof’ of causality.  But if there is some other factor that is causing this between-
country variation, and which is also linked to A1 beta –casein intake, then what could that
be?
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Figure 1.  Incidence of Type 1 diabetes and intake of A1 beta-casein excluding
cheese
(Data from Laugesen and Elliott 2003)
Figure 2.  Incidence of Type 1 diabetes and intake of milk protein excluding cheese
(Data from Laugesen and Elliott 2003)
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One of the key features of the Laugesen and Elliott analyses is that apart from Venezuela
they restricted themselves to developed countries.  This removed many of the potential
confounding factors.  (In fact removing Venezuela from the analysis –and this was tested
by Laugesen and Elliott- does not change the story in any way).  And they also tested for
everything else they could possibly think of.  It is indeed reasonable to dismiss a
relationship that has modest statistical significance as being potentially spurious, but it is
much more difficult to dismiss a relationship with a p-factor of less than 0.00001, and for
which there is no alternative explanation.
Since the publication of my book in September 200713 Dr Tony Merriman from Otago
University has criticised me on radio and in the popular media for placing too much
emphasis on this epidemiology.  His argument goes along the lines that the between-
country differences in Type 1 diabetes can be explained by latitudinal effects influencing
exposure to UV light and subsequent impact on vitamin D synthesis.  It is indeed true that
there is a cross correlation between latitude and intake of A1 beta casein.  This is because
many of the countries with high intake of A1 beta-casein are also high latitude countries.
But there are plenty of exceptions.  And the Laugesen and Elliott evidence shows that the
explanatory power of latitude (r2 =0.652=0.42) is only half that of A1 beta-casein.  In the
case of sunlight there was no meaningful relationship at all (M. Laugesen, pers comm).
So it is possible that the modest latitude correlation is being dragged along by its
association with A1 beta-casein but the evidence does not support the converse notion
that the strong A1 beta casein relationship is being dragged along by the modest
latitudinal relationship.
I would not want this debate about A1 beta-casein versus latitude to be taken as an
inference that Vitamin D is not relevant to Type 1 diabetes.  Almost certainly Type 1
diabetes is a multi-factorial disease, and I therefore remain very open to the notion that
Vitamin D is an important part of the overall story.  In particular, I note that there is
evidence that Type 1 diabetes typically reaches the clinical stage during winter when UV
radiation is lowest, and also that diabetics may have lower circulating levels of vitamin D
in their bloodstream.14  But what I do say very strongly, is that neither latitude nor
sunlight exposure can be used to explain away the relationships that we have between
Type 1 diabetes incidence and intake of A1 beta-casein.
Epidemiological links to heart disease
At an early stage of Bob Elliott’s work his proposals were forwarded to Dr Corran
McLachlan for peer review.  McLachlan’s expertise was more in relation to heart disease
than diabetes.  What immediately struck McLachlan was that the countries with high
Type 1 diabetes were also the countries that he knew from his own work to be countries
with high levels of heart disease (Figure 3).  This is a remarkable graph.  It suggests from
a public health perspective, and at a population level, that there are common factors that
influence the level of both Type 1 diabetes and heart disease.  Of course medical
scientists and doctors have all known for a long time that at the level of individuals there
are strong links between Type 2 diabetes and heart disease, but this graph is telling us
something quite different.  It is not saying at the individual level that people who have
Type 1 diabetes will get heart disease or vice versa.  But at the population level the two
diseases occur together.  Nor can we dismiss this relationship as simply being a collective
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of many modern-world environmental factors, because we can see from this figure that it
is only some developed countries that have a high incidence of these diseases.  This graph
was only published as a letter in the NZ Medical Journal15 and apart from in my book has
received scant exposure in the medical community.  It is a hugely important graph.
Figure 3 IHD death rate 1985 for males aged 30-69vs IDDM incidence for males
aged <15
(Reproduced from NZ Medical Journal 116 (1170)
Subsequently McLachlan explored whether, given that heart disease and Type 1 diabetes
occur in the same populations, and given that Type 1 diabetes is linked to A1 beta-casein,
is there also a direct link between heart disease and intake of A1 beta-casein?  The
answer, at the population level is a very strong ‘yes’ (Figure 4).16  McLachlan’s work was
subsequently confirmed by Laugesen and Elliott.17
I do not have time here to further develop the heart disease epidemiology in this paper,
except to mention that for many in this audience who are working with Type 2 diabetes,
there will be a very obvious question.  Given that Type 2 diabetes and heart disease are
very closely linked at the individual level through metabolic syndrome, does this suggest
a potential link between Type 2 diabetes and A1 beta-casein.  At this stage the answer has
to be that we do not know.  The work has not been done.  But I do draw attention to a
2005 paper in the European Journal of Clinical Nutrition, authored by Danish scientists,
and titled ‘High intakes of milk, but not meat, increase s-insulin and insulin resistance in
8-year-old boys’.18  They found that with high milk intakes both s-insulin and insulin
resistance approximately doubled.  Also, research with dairy cattle has shown that
casomorphins injected into the digestive system reduce the subsequent insulin responses
to glucose infusions.19
It is now time to move away from the epidemiology, because epidemiology is just one of
the many strands of relevant evidence that build up the rich picture of Type 1 diabetes
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and A1 beta casein.  Some of those who argue against the A1/A2 hypothesis claim that
the evidence is essentially limited to epidemiology.  Do not believe it.
Figure 4.  Death rates from ischaemic heart disease in males aged 30-69 in 1985
(Redrawn from McLachlan (2001) Medical Hypotheses 56(2):265
Biochemistry
The only difference between bovine A1 beta-casein and A2 beta casein is one amino acid
out of 209.  Whereas A2 beta-casein has a proline at position 67, A1 beta-casein has a
histidine.  However, this can have a profound effect on the release during digestion of a
particular a peptide (protein fragment).  Specifically, the histidine at position 67 in A1
beta-casein facilitates the release of the opioid peptide beta-casomorphin7 (BCM7) upon
digestion, whereas the proline acts as a major barrier to this release.20, 21
BCM7 is particularly stable on account of three of its seven amino acids being prolines.
However, it is evident that BCM7 can be degraded by the enzyme dipeptidyl peptidase 4
(DPP4) that is found on cell surfaces within mesenteric tissues.22  It is also apparent that
in many people the intestinal lining combined with the presence of DPP4 is sufficient to
prevent the BCM7 from passing through in to the bloodstream.  However, there is also
evidence that in people who for a range of reasons have ‘leaky guts’ it is possible for
BCM7 to pass through.23, 24
There are many reasons why individuals can suffer from leaky guts.  Newborn babies
have permeable intestines to allow macro molecules in colostrum to pass through.  In
later life, permeability can arise, either short term or long term, from a range of health
conditions such as Coeliac disease, ulcerative colitis, Crohn’s disease, and stomach
ulcers.  Of particular relevance in relation to stomach ulcers is that the historical
treatment of ulcers with a high milk diet (such as the Sippy and similar diets) was shown
to lead to a very high death rate from heart disease relative to other diets.25
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Figure 5.  Formation of beta-casomorphin.
Scientists working on Type 2 diabetes will be aware that there are a several clinical trials
underway looking at whether drugs that reduce DPP4 production might lead to reduced
insulin levels in the blood.  An unintended and potentially important side effect could be
reduced ability to breakdown BCM7.
Pharmacology
Bovine BCM7 is a strong opioid.26, 27  It can be counteracted by administration of
naloxone but BCM7 has very strong binding affinity and ten times more naloxone is
required to counteract a molecule of BCM7 than is required to counteract a molecule of
ordinary morphine.  Animal trials have shown that in rodents BCM7 easily crosses the
blood brain barrier and leads to bizarre behaviour patterns akin to those observed in
autism and schizophrenia.28, 29, 30  Several groups have shown that autistic humans
typically excrete BCM7 in their urine.31, 32, 33  This can only have come from milk.
Humans milk can also release BCM7 but apparently only in small quantities.  Also,
human BCM7 is different to bovine BCM7 with the Pro-Gly sequence (positions 4 and 5)
replaced by Val-Glu.  Human BCM7 is a much weaker opioid than bovine BCM7.
Immunology
There is a broad range of evidence suggesting that persons with Type 1 diabetes have
enhanced levels of antibodies to beta-casein.34, 35  How this should be interpreted is open
to debate.  It is possible that this is simply a manifestation of Type 1 diabetics being
particularly sensitive to antibody reactions.  However research by German scientists has
shown that for persons with Type 1 diabetes the  ratio of A1 to A2 beta-casein antibodies
is higher than for case controls (p<0.001).36  In addition to the literature published in
scientific journals, the NZ Dairy Board (now Fonterra) has a patent linking Type 1
diabetes with A1 beta–casein (PCT/NZ95/0014) that presents evidence showing that
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IgG(1+3) antibodies discriminate against A1 beta-casein relative to A2 beta-casein
(p=0.003).
Finding the specific mechanism
Italian scientist Paulo Pozzilli has pointed out in a patent application (US patent
6,750,203) that there is a sequence of four amino acids at the end of the BCM7 molecule
(Pro-Gly-Pro-Ile) that is identical to a sequence within the GLUT2 molecule, which is the
glucose transporting molecule inside insulin-producing cells in the pancreas.  He has
hypothesised that antibodies to BCM7 are attacking through cross-reactivity the GLUT2
molecule and thereby destroying the insulin-producing cells.  There is no proof that
Pozzilli is correct, but it is a plausible hypothesis that brings together the known
biochemistry, pharmacology and immunology into a coherent hypothesis. Other authors
have pointed out that sequence homologies exist between beta-casein and several
pancreatic beta-cell molecules.37.
Human trials
There have been no human trials specifically comparing the diabetogenic effects of A1
beta casein and A2 beta-casein.  However, Finnish scientists led by Suvi Virtanen have
monitored milk consumption by the siblings of diabetic children.38  These siblings were
non-diabetic at the start of the monitoring but were considered on account of specific
genetic factors to be high risk.  They found that those drinking more than 540ml of milk
per day were more than five times as likely to become diabetic than those drinking less
than this amount (p<0.01). There is further preliminary data from Finland as part of the
TRIGR program that babies aged 6-8 months fed casein hydrolysate rather than standard
infant formula are significantly less likely to develop ‘positivity for islet cell antibodies
(p=0.02) and at least one autoantibody (p=0.03)’.39
More on animals
There is one paper that has been widely used to discredit the link between A1 beta-casein
and Type 1 diabetes.  It is a multi country trial using NOD mice in NZ and Britain, and
BB rats in Canada.  The diets were supplied by the NZ Dairy Research Institute (NZDRI)
(then part of the NZ Dairy Board, subsequently part of Fonterra).  The results were
published in Diabetologia.40
There is a huge problem with this trial that was never acknowledged in the published
paper.  It was known both to the supplier of the diets (NZDRI), and to at least four of the
authors (one of whom was from NZDRI and remains a senior Fonterra employee) that
half of the A2 diets were contaminated with large amounts of BCM7.  And this was
known well over a year before the paper was submitted for publication.  The detailed
documentation for the above statements is provided in my book.41  What is also
remarkable is the way that three of the authors of this paper have subsequently argued in
other forums that, given the results of this trial, a link between A1 beta-casein and Type 1
diabetes is unlikely.42, 43  In fact, the results of this trial, once the contaminated diets are
removed, are broadly supportive of such a link with statistically significant results for the
BB rats.
I regard the issue of scientific integrity involved in this saga as one which the diabetes
research community has to take up.  My own attempts to get Diabetologia to investigate
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this issue have been unsuccessful.  The documentation, both in regard to the
contamination and the pre publication knowledge of the authors concerning this
contamination, is irrefutable.
Some other health conditions linked to A1 beta-casein
The epidemiology of heart disease was introduced earlier in this paper.  Other evidence
relevant to heart disease includes Australian evidence that rodents fed A1 beta casein are
susceptible to the development of arterial plaque whereas this does not occur with A2
beta-casein.44  Also, European research has shown that BCM7 can act as a catalyst in the
oxidation of LDL.45
Key evidence linking BCM7 to symptoms of autism and schizophrenia (animal and
human trials) has also been introduced earlier in this paper in relation to the biochemistry
and pharmacology of BCM7.  However, the detailed issues linking symptoms of autism
and schizophrenia with BCM7 are far too broad to be covered here.
There are additional autoimmune diseases for which there is existing circumstantial
evidence of a link with casein but for which the evidence remains at the hypothesis
stage.46, 47, 48  The key issue linking many of these autoimmune conditions may be a leaky
gut.
Recently it has also been shown that BCM7 stimulates production of mucins, which are
the proteins found within mucus, and which make the mucus sticky.49  This is consistent
with the widely held belief that milk leads to mucus in the throat and nose.  It is also
apparent, although based on observational evidence and not tested in controlled clinical
situations, that a considerable number of people who have previously considered
themselves intolerant to milk with symptoms of nausea and diarrhoea, can however drink
A2 milk. Indeed it is these experiences that have led many consumers to become A2
believers.
The counter attack
The New Zealand dairy industry had to make a decision early on as to how to deal with
the beta-casein issue.  Back in 1997 and thereabouts there was serious discussion both
within the NZDRI and within NZ Dairy Group (NZDG), which was then the largest of
the NZ dairy co-operatives, as to whether or not the national herd should, on
precautionary grounds, be converted to A2.  (I hold unpublished documentation relating
to that discussion).  A reliable source tells me it was a close decision for NZDG, but in
the end, commercial pressures won out.  It would have been a challenge during the
transition phase to market milk containing A1 beta-casein.  So a decision was made to do
nothing overt, and presumably hope the issue would fade away.  At that time there was of
course much less evidence available than is currently the case, and so perhaps that
decision was indeed reasonable.  However, the evidence even then was sufficiently
convincing that since that time the A1/A2 status of all of the artificial insemination bulls
in New Zealand has been recorded.
From about the year 2000 and onwards, and apparently linked to the formation of A2
Corporation as a commercial entity hoping to exploit patents and trademarks associated
with A2 beta-casein, the mainstream dairy industry decided to counter attack.  This attack
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included a number of poster papers authored and presented by Fonterra’s scientists at the
International Dairy Federation Conference in 2002.  These were subsequently published,
but only as non refereed poster papers, in the Australian Journal of Dairy Technology.
The attack also included a conference review paper in the Proceedings of the NZ Society
of Animal Production in 2002,50 where supposedly new results were presented (but
without supporting data) showing a lack of correlation between A1 beta-casein and heart
disease.  Although the dairy industry public relations machine has subsequently used
these papers to claim that hypotheses associated with A1 beta-casein have been refuted,
none of this work has ever been published as peer reviewed.  None of these papers can be
found through a search of the major electronic medical database ‘PubMed’ despite more
than 16 million scientific citations being listed there. The supposed findings and major
flaws in each of these papers are set out in my book.51
Then in 2004 Fonterra produced a 12 page document which they distributed widely to
people who they thought might be influential.  However, this document has not only
never been published, but it would also seem to have never appeared on any website
where it might be submitted to closer scrutiny.  It included many erroneous statements,
and a number of quotes taken seriously out of context.  For anyone reading this document
with no previous knowledge, it would have seemed a very convincing counter attack, and
any reader could have been forgiven for thinking that the whole issue of A1 and A2 was
commercial, non scientific, and a media beat up.
More recently, in August 2007, the overarching Australian dairy industry group called
Dairy Australia produced a 17 page document along the same lines.  Once again, this was
sent to influential people but it appears to have never been placed in any public arena
where it might be countered.
Back in 2005 Professor Truswell, presenting as a University of Sydney Professor of
Nutrition, and without disclosure of industry associations, authored a paper published in
the European Journal of Clinical Nutrition, which absolutely trashed the A1/A2
hypothesis.52  This then lead to a series of correspondence within the journal but still
without identification of Truswell’s associations.53, 54, 55  Professor Truswell has
subsequently admitted in writing that he was employed by Fonterra and received payment
from them for reviewing issues surrounding A1 and A2, although not specifically for
writing the paper for the EJCN.56  He was also Fonterra’s expert witness in unsuccessful
Intellectual Property Office hearings relating to claims by Fonterra against an A2
Corporation patent.  Clearly, it is not acceptable, and even more so in the case of a review
publication where specific material to be included or excluded is dependent on author
judgements, to not disclose industry associations.  Other scientists have subsequently
cited Truswell’s supposedly independent findings without knowledge of his conflicts of
interest.57
Following the publication of the Laugesen and Elliott paper in 2003, the New Zealand
Food Safety Authority (NZFSA) set up a review of issues associated with A1 and A2 beta
casein.  That review was undertaken by one of our commentators today, Professor Boyd
Swinburn.  A key message of that review, based on analysis of 38 published papers, was
one of uncertainty, and that this uncertainty needed to be communicated to the public.
However, the NZFSA chose to portray the findings of the review as being that all milk
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was safe.  Professor Swinburn privately remonstrated with the NZFSA for the way they
reported his findings and referred to ‘NZFSA spin’.  I have obtained that correspondence
through the Official Information Act.  Professor Swinburn further explained to them his
position in terms of risk management with the following analogy. .  ‘…if I had a child
with Type 1 diabetes and was due to have another and I could easily obtain and afford A2
milk or formula, I would certainly use it for the next child because the cost/benefit is low
because of the potentially very large benefit of preventing Type 1 diabetes.’
Professor Swinburn also remonstrated with the NZFSA for the way that they released his
report at precisely the time when he had told them he would not be available for media
comments.  NZFSA official Carole Inkster apologised, but also opined:  ‘…we did not
believe that [your unavailability] was a distraction in so far as the media were not able
to engage on points of science unnecessarily and potentially beat up the issue.’
The actions of the NZFSA in relation to A1 and A2 are currently under investigation in a
review of NZFSA processes being undertaken by Dr Stuart Slorach from Sweden.
However, NZFSA Director Andrew McKenzie, in publicly announcing the setting up of
this review, emphasised its importance in terms of ‘burying the issue once and for all’,
and also in relation to maintaining public perceptions relating to NZFSA integrity.  I will
await the outcome with great interest, but I do comment here that I would have liked to
see much greater separation of NZFSA personnel from the Review.  The Slorach review
needed to be seen as independent.  It should have been managed by the State Services
Commission and not by the NZFSA itself.  My own analysis of the NZFSA processes,
based on published documents and information obtained under the Official Information
Act, is available on the internet.58, 59
A second international review has also been announced in relation to the science behind
the A1/A2 hypothesis.  This is to be undertaken by the European Food Safety Authority.
At this stage there are no final terms of reference from the EFSA.  It is essential that these
terms of reference, unlike the Swinburn Review, ensure that not only clinical evidence
but the underlying biochemistry, pharmacology and immunology are also considered.  If
clinical evidenced based on the ‘gold standard’ double blind trial were the only
acceptable criteria, then we would still be saying there was no evidence linking smoking
to lung cancer!
In relation to Type 1 diabetes there appears to be only one counter argument that is
worthy of consideration.  It is the fact that although the A1/A2 epidemiology provides a
remarkable explanation for the between-country variations in Type 1 diabetes incidence,
it does not explain why that incidence level has been increasing at approximately 3% per
annum.   However, there are several other factors that may explain this in the context of a
disease which is widely accepted to be multi-factorial.  One hypothesis is that of Bob
Elliott, who believes that the answer may lie with glycated (AGE) products in general,
and in particular glycated BCM7.60.  It is also important to recognise that in an
autoimmune disease which requires multiple ‘triggers’ to line up together for the disease
to occur, it may only require removal of any one of these triggers to create a very large
impact on overall disease incidence.
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Moving forward
There are two fronts on which there is a need for urgent movement.  The first relates to
dispassionate analysis and communication of the very extensive body of knowledge that
does exist.  As part of this communication, there is a need to bring into the open the way
that industry politics have allowed the debate to be commandeered.  This current paper is
one part of this communication process which others now need to take up.  There is a lot
more that needs to be communicated, not only in relation to Type 1 diabetes but also in
relation to heart disease, autism, schizophrenia, and a range of other autoimmune
diseases.
Medical scientists and organisations working with diabetes and these other diseases in
which A1 beta-casein is implicated have an important role in getting the message out to
the public.  An essential part of this message is that from a human heath perspective there
is only potential ‘upside’ and no ‘downside’ associated with a move to A2 milk, which is
the original natural form.  Once key health organisations communicate that message, then
a comprehensive supply of A2 milk can be quickly organised.  It is also important to
understand that although there are key patents and trademarks owned by one particular
organisation, no company or organisation owns the A2 gene.  Anyone can produce milk
that is free of A1 beta-casein.
The second front on which action is needed is in relation to additional research.  This
needs to be occurring at several levels.  It is something that Professor Swinburn called for
in his 2004 report to the NZFSA, but that message was ignored and effectively buried.
At a very simple level we need ongoing monitoring of the levels of A1 beta-casein in
commercial milk supplies, and how that level is changing.  This needs to be done
internationally.  In relation to Type 1 diabetes we also need improved ascertainment of
diabetes incidence rates and how that too is changing.
Despite there being more than 230 papers in the PubMed database that can be found
using the keyword of ‘casomorphin’ there is still much that we do not know about the
biochemistry and pharmacology of this peptide.
It would be extremely valuable if a trial comparable to the current TRIGR trial61 was
undertaken using specifically A1 and A2 beta-casein.  However, given the existing body
of knowledge, there may be ethical issues associated with subjecting babies to A1 beta-
casein.
But finally, the question has to be addressed, both in relation to action and the
precautionary principle, when is ‘enough enough’.  In the case of New Zealand, LIC, who
are the major suppliers of semen to NZ dairy farmers, and who also supply semen
internationally, have said the following62:
LIC could, within 48 hours, respond to a market directive to move to A2 milk (i.e.
only put A2 bulls forward for collection). This would mean that, within eight to ten
years, virtually every cow in New Zealand would be A2.  This shift – if directed by
consumer demand – could be done without compromising other genetic qualities.
Why is it not happening?
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****
Note: This version of the paper compared to an earlier website version contains a
restatement of one sentence on the immunology (p9) to more accurately reflect the
findings of German scientists re antibodies to A1 and A2 beta-casein. [Correction made
14/5/08]
Further Information.
More comprehensive information on issues discussed in this paper can be found in my
book “Devil in the Milk” published September 2007 by Craig Potton Publishers and
available for purchase internationally at:
www.devilinthemilk.co.nz
Disclosure of Interest
As Lincoln University’s Professor of Farm Management and Agribusiness I have close
professional links with all issues affecting the New Zealand dairy industry, and I
undertake significant media commentary on a range of agribusiness issues.  I have
undertaken no consultancies for A2 Corporation, Fonterra, or the former NZDRI in
relation to either the issue of A1 and A2 beta-casein, or on any other topic.  Prior to June
2007 I had family members who owned a very minor shareholding in A2 Corporation.  I
have never personally owned shares on A2 Corporation. The family shares were
purchased on market under normal market conditions.  The existence of these family-
owned shares was acknowledged at the time in articles relating to A2 that I wrote.  To
avoid any perceptions of direct or indirect interest, and prior to the publication of my
book, my family sold their shares in June 2007.
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